Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

MRC Technology and Oxford University Collaborate

Published: Thursday, November 14, 2013
Last Updated: Thursday, November 14, 2013
Bookmark and Share
The project will screen TRESK potassium channel activators involved in migraine pain control.

MRC Technology announce it is collaborating with Dr Zameel Cader at Oxford University’s Nuffield Department of Clinical Neurosciences, to screen selective and potent potassium channel activators to develop novel therapeutic interventions in migraine. Drawing on MRC Technology’s commercialisation expertise in drug discovery, the project focusses on bringing to clinic more effective pain treatments arising from the work of Dr Cader’s group in identifying KCNK18, the first gene underlying typical migraine. 

KCNK18 encodes a tandem-pore background potassium channel, TRESK, which is linked to causing migraines and controls the sensitivity of pain nerves in the brain. If TRESK is faulty or inactive, the body’s threshold to pain can be significantly lowered. Migraine is the most common neurological disorder, with prevalence estimated at 18.2% in females and 6.5% in males, and is characterised by a severe, recurring headache, often accompanied by nausea, vomiting and increased sensitivity to light and sound.

Dr Justin Bryans at MRC Technology, said: “We are delighted to be working with Dr Cader and his team who have made such a significant discovery in the underlying causes of migraine. We are hopeful that our collaboration will lead to treatments that could not only prevent migraines, but could potentially result in a more general pain therapy with even wider impact." 

“Migraine is a major cause of disability worldwide and it has been estimated to be the most costly neurological disorder in Europe,” commented Dr Cader. “We have made a major step forward in our understanding of why people suffer with migraine and with MRC Technology’s wealth of drug discovery experience, we look forward to working with them to bring novel treatments to market.” 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology Negotiates License with Bio-Techne for MRC’s GOPAL Protein Synthesis Technology
Technology enables production of ubiquitin reagents and other proteins for use in drug discovery.
Wednesday, August 27, 2014
MRC Technology, AstraZeneca Renew Target Discovery Collaboration
Initiative brings together global expertise to share compound libraries and streamline drug discovery.
Thursday, July 03, 2014
MRC Technology Sells its MCRs Programme to Pfizer
Small molecules developed in collaboration with Queen Mary University of London.
Thursday, June 19, 2014
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
Initiative brings together global expertise to streamline drug discovery.
Wednesday, May 14, 2014
£3m Dementia Consortium Launched
New Consortium aims to boost dementia drug discovery by uniting charity, academic and private sectors in search for new treatments.
Wednesday, December 11, 2013
MRC Technology and Renishaw Diagnostics Collaborate
Initiative combines expertise to accelerate clinical diagnostic screening.
Thursday, October 03, 2013
MRC Technology Forms Alliance with World Leading Translational Research Centres
The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network.
Monday, January 21, 2013
MRC Technology Launches Small Molecule Compound Library Access Scheme
Subset of compound library to be made available to academic researchers free of charge.
Thursday, September 20, 2012
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos